Small noncoding RNA TY2 enhances efferocytosis and improves outcomes in a mouse model of sepsis
Open Access
- 22 January 2026
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (5)
Abstract
TY2 is a drug based on a natural compound with potent anti-inflammatory effects. TY2 improved outcomes in mice with severe bacterial infection.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01 HL124074,R01 HL142579,HL155346,HL116273)
This publication has 7 references indexed in Scilit:
- Augmentation of DNA exonuclease TREX1 in macrophages as a therapy for cardiac ischemic injuryScience Translational Medicine, 2025
- Oral Bioavailability of a Noncoding RNA Drug, TY1, That Acts on MacrophagesJournal of Extracellular Biology, 2025
- Activin A activation of Smad3 mitigates innate inflammation in mouse models of psoriasis and sepsisJournal of Clinical Investigation, 2025
- Deconstructing Regenerative Medicine: From Mechanistic Studies of Cell Therapy to Novel Bioinspired RNA DrugsCirculation Research, 2024
- Non-coding RNA yREX3 from human extracellular vesicles exerts macrophage-mediated cardioprotection via a novel gene-methylating mechanismEuropean Heart Journal, 2024
- Cytokine profiles as markers of disease severity in sepsis: a multiplex analysisCritical Care, 2007
- RODENT MODELS OF INTRA-ABDOMINAL INFECTIONShock, 2005